Park IK, Qian D, Kiel M, et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells[J]. Nature, 2003, 423(6937): 302-305.
[2]
Zhang X, Wang CX, Zhu CB, et al. Overexpression of Bmi-1 in uterine cervical cancer: correlation with clinicopathology and prognosis[J]. Int J Gynecol Cancer, 2010, 20(9): 1597-1603.
[3]
[ 6 ] Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases[J]. Cancer Res, 2000, 60(24): 7075-7083.
[4]
[ 7 ] Liao SY, Darcy KM, Randall LM, et al. Prognostic relevance of carbonic anhydrase-Ⅸ in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study[J]. Gynecol Oncol, 2010, 16(3): 452-458.
[5]
[ 8 ] Woelber L, Kress K, Kersten JF, et al .Carbonic anhydraseⅨ in tumor tissue and sera of patients with primary cervical cancer[J]. BMC Cancer, 2011, 11(11): 12.
[6]
[ 9 ] Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface[J]. Nat Rev Cancer, 2004, 4(1): 45-60.
[7]
Rose MC, Voynow JA. Respiratory tract mucin genes and mucin glycoproteins in health and disease[J]. Physiol Rev, 2006, 86(1): 245-278.
[8]
Gipson IK, Blalock T, Tisdale A, et al. MUC16 is lost from the uterodome (pinopode) surface of the receptive human endometrium: in vitro evidence that MUC16 is a barrier to trophoblast adherence[J]. Biol Reprod, 2008, 78(1): 134-142.
[9]
Togami S, Nomoto M, Higashi M, et al. Expression of mucin antigens (MUC1 and MUC16) as a prognostic factor for mucinous adenocarcinoma of the uterine cervix[J]. J Obstet Gynaecol Res, 2010, 36(3): 588-597.
[10]
Hasegawa K, Kato R, Torii Y, et al. The relationship between ERCC1 expression and clinical outcome in patients with FIGO stage Ⅰ to stageⅡ uterine cervical adenocarcinoma[J]. Int J Gynecol Cancer, 2011, 21(8):1479-1485.
[11]
Alberts B, Johnson A, Lewis J, et al. Molecular biology of the cell[M]. 5th ed. New York: Garland Science, 2008.
[12]
Kim YI, Lee A, Lee BH, et al. Prognostic significance of syndecan-1 expression in cervical cancers[J]. J Gynecol Oncol, 2011, 22(3): 161-167.
[13]
Shannan B, Seifert M, Leskov K, et al. Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer[J]. Cell Death Differ, 2006, 13(1): 12-19.
[14]
Zellweger T, Chi K, Miyake H, et al. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin[J]. Clin Cancer Res, 2002, 8(10): 3276-3284.
[15]
Miyake H, Hara S, Arakawa S, et al. Over expression of clusterin is an independent prognostic factor for nonpapillary renal cell carcinoma[J]. J Urol, 2002, 167(2 Pt 1): 703-706.
[16]
He LR, Liu MZ, Li BK, et al. Clusterin as a predictor for chemoradiotherapy sensitivity and patient survival in esophageal squamous cell carcinoma[J]. Cancer Sci, 2009, 100(12): 2354-2360.
[17]
Watari H, Kinoshita R, Han Y, et al. Prognostic significance of clusterin expression in advanced-stage cervical cancer treated with curative intended radiotherapy[J]. Int J Gynecol Cancer, 2012, 22(3): 465-470.
[18]
[ 1 ] Parkin DM, Bray F, Ferlay J, et al. Global Cancer statistics, 2002[J]. CA Cancer J Clin, 2005, 55(2): 74-108.
[19]
[ 2 ] Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world[J]. J Clin Oncol, 2006, 24(14): 2137-2150.
[20]
[ 3 ] Bezerra AL, Martins MR, Bezerra SM, et al. ClassⅡ radical hysterectomy for stage Ⅰ-ⅡA cervix Cancer: prognostic factors associated to recurrence and survival in a Northeast Brazil experience[J]. J Surg Oncol, 2011, 104(3): 255-259.
[21]
[ 4 ] Potter C, Harris AL. Hypoxia inducible carbonic anhydraseⅨ, marker of tumour hypoxia, survival pathway and therapy target[J]. Cell Cycle, 2004, 3(2): 164-167.
[22]
[ 5 ] Robertson N, Potter C, Harris AL. Role of carbonic anhydraseⅨ in human tumor cell growth, survival, and invasion[J]. Cancer Res, 2004, 64(17): 6160-6165.
[23]
Sobti RC, Singh N, Hussain S, et al. Deregulation of STAT-5 isoforms in the development of HPV-mediated cervical carcinogenesis[J]. J Recept Signal Transduct Res, 2010, 30(3): 178-188.
[24]
Chen HH, Chou CY, Wu YH, et al. Constitutive STAT5 activation correlates with better survival in cervical cancer patients treated with radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2012, 82(2): 658-666.
[25]
Azuma K, Komohara Y, Sasada T, et al. Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy[J]. Cancer Sci, 2007, 98(9): 1336-1343.
[26]
Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy[J]. N Engl J Med, 2006, 355(10): 983-991.
[27]
Park JS, Jeon EK, Chun SH, et al. ERCC1 (excision repair cross-complementation group 1) expression as a predictor for response of neoadjuvant chemotherapy for FIGO stage 2B uterine cervix cancer[J]. Gynecol Oncol, 2011, 120(2): 275-279.
